arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Amneal Pharmaceuticals, Inc.

AMRX
$18.15 ▲ +0.07 (+0.39%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
38 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Neutral
auto_awesome

Analytical Summary

Amneal Pharmaceuticals, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $5.7B
Dividend Yield
Revenue Growth 3.9%
Op. Margin 19.6%
ROIC 5.5%
FCF / Share $-0.11
Trailing P/E 90.8x
Price / Book
FCF Yield
Debt / Equity -56.63
info Valuation on last close. End-of-day price, Aug 7, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$722.52M
↑ +3.9%
Net Income Profit after all expenses
$62.26M
↑ +410.5%
Operating Margin Operating profit as % of sales
19.6%
↑ +42.6% 63th
FCF / Share Free cash flow per share
$-0.11
↓ -497.3%
Long-Term Debt Long-term obligations
$2.57B
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
54
Returns
8
Financial Health
80
Cash Quality
93

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters